11:32 AM EDT, 06/03/2024 (MT Newswires) -- Brainsway ( BWAY ) said Monday the US Food and Drug Administration has granted a label expansion for its Deep Transcranial Magnetic Stimulation system to treat major depressive disorder patients ages 22 to 86, changing the upper age limit of 68.

This makes BrainsWay Deep TMS the first and only form of TMS indicated for the treatment of patients over the age of 68 suffering from MDD, including those with comorbid anxiety symptoms, the company said.

Shares of the company rose about 5% in recent trading.

Price: 6.61, Change: +0.32, Percent Change: +5.09